<i>KMT2D</i> mutations and <i>TP53</i> disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL studySimone Ferrero, Gianluca Gaïdano, Davide Rossi et al.|Haematologica|2019Cited by 137
The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30‐year experienceAlessandro Broccoli, Pier Luigi Zinzani, Lisa Argnani et al.|American Journal of Hematology|2021Cited by 17
Efficacy and Safety of Frontline Single‐Agent Rituximab in Extranodal Marginal Zone LymphomaCamilla Mazzoni, Pier Luigi Zinzani, Giulia Gabrielli et al.|European Journal Of Haematology|2024Cited by 3
Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world studyBeatrice Casadei, Pier Luigi Zinzani, Lisa Argnani et al.|Blood Advances|2025Cited by 2
Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practiceCinzia Pellegrini, Pier Luigi Zinzani, Beatrice Casadei et al.|Annals of Hematology|2025Cited by 2